Compare ACADIA Pharmaceuticals Inc. (ACAD) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs BigBearai Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while BigBearai Holdings Inc trades at $3.33 (market cap $1.64B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.7× BigBearai Holdings Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BBAI | |
|---|---|---|
Market Cap | $4.49B | $1.64B |
Sector | Health | Technology |
52-Week High | $28.06 | $8.91 |
52-Week Low | $20.06 | $3.05 |
Enterprise Value | $3.69B | $1.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BBAI trades at $3.58, up 1.42% today, but technical indicators signal a bearish trend with strong selling pressure. The company reported a net loss of $293.91 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights expansion into AI-powered airport security and government contracts, though high SG&A expenses and persistent losses remain concerns. Analyst consensus is cautious, with 75% hold ratings.
The outlook is challenged by ongoing losses and rich valuation, but growth in AI contracts and backlog offers potential upside. Key risks include execution on profitability, competitive pressures, and reliance on government spending. Investors should weigh the high-risk, high-reward profile amid volatile market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
